Abstract
The cautious optimism of this quotation may well be applied to cancer research in general and the role of antiestrogens in particular. The fact that the malignant cell often retains some sensitivity to signals which control growth and function in their normal counterpart - allows us to hope. The instability and heterogeneity of any cancer cell population, with its inherent dynamics and ability to bypass apoptotic regulation, considerably weakens our ability to predict cause and effect.
“With high hope for the future, no prediction is ventured”
(A. Lincoln)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barai E, Nagy E, Kangas L, Berczi I (1996): Immunotherapy of the SL2–5 murine lymphoma with natural killer cells and Tamoxifen or Toremifene. In press, Cancer
Bogden AE, Keyes SR, Grant W, Silver M, Batista LI, LePage D (1995): Estrogen Sensitivity and the Therapeutic Benefit of Lanreotide Tamoxifen Combination in the Treatment of Breast Tumors. Proc AACR 36:523
Buzoni R, Biganzoli L, Bajetta E, Celio L, Fornasiero A, Mariani L, Zilemno N, Di Bartolomeo M, Di Leo A, Arcangeli G, Aitini E, Farina G, Schieppati GH, Galuzzo D, Marinetti A (1995): Combination Goserelin and Tamoxifen Therapy in Premenopausal Advanced Breast Cancer: a Multicentre Study by the ITMO Group.Brit J Cancer 71:1111–1114
Carthew P, Rich KJ, Martin EA, DeMattheis F, Lim CK, Manson MM, Festing FW, White IHN, Smith LL (1995): DNA damage as assessed by 32P- postlabelling in three rat strains exposed to dietary Tamoxifen. Carcinogenesis 16:1299–1305
Clarke R, van den Berg HW, Murphy RF (1990): Reduction of the Membrane Fluidity of Human Breast Cancer Cells by Tamoxifen and 17 beta-Estradiol. J Natl Cancer Inst 82:1702–1705
DeFriend DJ, Howell A (1994): Tamoxifen withdrawal responses - chance observations or clinical clues to antioestrogen resistance? The Breast 3:199–201
Fernö M, Baldetorp B, Borg A, Brouilett JP, Olsson H, Rochefort H, Sellberg G, Sigurdsson H, Killander D (1994): Cathepsin D, Both a Prognostic Factor for the Effect of Adjuvant Tamoxifen in Breast Cancer.Europ J Cancer 30A:2042–2048
Freitas I, Baronzio GF (1994): Neglected Factors in Cancer Treatment: Cellular Interactions and Dynamic Microenvironment in Solid Tumors. Anticancer Res 14:1097–1102
Graham ML, Smith JA, Jewett PB, Horwitz KB (1992): Heterogeneity of Progesterone Receptor Content and Remodelling by Tamoxifen Characterize Subpopulations of Cultured Human Breast Cancer Cells: Analysis by Quantitative Duel Parameter Flow Cytometry. Cancer Res 52:593–602
Horwitz KB (1995): Editorial: When Tamoxifen Turns Bad. Endocrinol 136:821–823
Howell A, Dodwell DJ, Anderson H (1992): Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611–617
Kellen J A (1994): Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton, pp 93–125
King CM (1995): Tamoxifen and the induction of cancer. Carcinogen 16:1449–1454
Levy GB (1994): Merchandising science. Amer Lab 6:6–8
Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W (1995): Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206–4210
Markman M (1993): Why does a higher response rate to chemotherapy correlate poorly with improved survival? J Cancer Res Clin Oncol 119:700–701
Margolese R (1994): The challenge of breast cancer. Lancet 343:1086
Marsigliante S, Leo G, D’Elia M, Vinson GP, Greco S, Puddefoot J, Storelli C (1994): Relationships Between Tamoxifen Binding Proteins in Primary Breast Cancer Biopsies. Europ J Ca 30A: 1694–1700
Mestdagh N, D’Hooghe MC, Lantoine D, Henichart JP (1995): Expression of a tumour-suppressor gene and of various proto-oncogenes in human and murine adriamycin-resistant and sensitive cell lines. Int J Oncol 6:1255–1260
Millon R, Nicora F, Muller D, Eber M, Klein-Soyer C, Abecassis J (1989): Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin Expl Metastasis 7:405–415
Pollak M (1995): Potential Impact of Genetic Testing on Cancer Prevention Trials, Using Breast Cancer as an Example. J Natl Cancer Inst 87:1557
Rajah TT, Pento JT (1995): The Mutagenic Potential of Antiestrogens at the hprt Locus in V79 Cells. Res Coram Molec Pathol Pharmacol 89:85–92
Shannon JA, Harnett PR (1994): Multiple responses to tamoxifen in advanced breast cancer - clinical and biological implications. The Breast 3:235–237
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Birkhäuser Boston
About this chapter
Cite this chapter
Kellen, J.A. (1996). Conclusions. In: Kellen, J.A. (eds) Tamoxifen. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4092-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4092-1_17
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8648-6
Online ISBN: 978-1-4612-4092-1
eBook Packages: Springer Book Archive